ESMO 2022 | Moving ADCs to first-line therapy in metastatic HER2+ breast cancer

Mattia Rediti, MD, Institut Jules Bordet, Anderlecht, Belgium, comments on moving antibody-drug conjugates (ADCs) to earlier lines of therapy in treating metastatic HER2+ breast cancer. Whilst ADCs such as trastuzumab deruxtecan are currently utilized in second-line settings, they have the potential to be used in first-line settings. Dr Rediti additionally talks on the need to reinterpret biomarkers if ADCs are administered in earlier settings. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.